HHS awards BioCryst $12 million contract

The Department of Health and Human Services (HHS) said Tuesday that its Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $12 million contract for an Ebola treatment to BioCryst Pharmaceuticals, Inc.

This contract would allow BioCryst to further develop its candidate treatment for Ebola virus disease that has been shown to be effective in nonhuman primate models. In these tests, the drug BCX4430 prevented the reproduction capability of Ebola and Marburg viruses. This indicates that it could be a potential broad spectrum option for hemorrhagic fevers.
The contract could be extended to August 2017 and up to $35 million.
“Developing drugs and vaccines to protect against Ebola has been a long-term goal of the U.S. government,” ASPR's Biomedical Advanced Research and Development Authority (BARDA) Director Robin Robinson said. “We are making progress quickly to develop product candidates for clinical evaluation and to make products available that protect against this virus.”

The treatment is currently in the first phase of clinical trials with healthy volunteers with funding from the National Institutes of Health. During this time, BARDA support will enable the enhancement of production capabilities in order to scale up manufacturing.
BCX4430 is the first treatment of this kind to receive BARDA support.

Organizations in this Story

Biomedical Advanced Researc and Development Authority (BARDA) National Institutes of Health

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.